Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach

Bassi, Zuni I., Fillmore, Martin C., Miah, Afjal H., Chapman, Trevor D., Maller, Claire, Roberts, Emma J., Davis, Lauren C., Lewis, Darcy E. +9 more·2018·ACS Chemical Biology

DOI 10.1021/acschembio.8b00705

Cited by (197)

Items 101–197 of 197

Proteolysis-targeting Chimeras for Targeting Protein for Degradation
Jianguo Qi, Gang Zhang · 2019 · Future Medicinal Chemistry
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Sarah F. Giardina, Elena Valdambrini, J. David Warren, Francis Barany · 2021 · Current Cancer Drug Targets
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras
Ritesh P. Bhole, Sapana Patil, Harshad S. Kapare, Rupesh V. Chikhale, Shailendra Shivaji Gurav · 2024 · Current Topics in Medicinal Chemistry
Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules
Alexandré Delport, Raymond Hewer · 2019 · Molecules
Cereblon: promise and challenges for combating human diseases
Hyoung Kyu Kim, Jung Eun Seol, Sang Woo Ahn, Seungje Jeon, Chul‐Seung Park, Jin Han · 2021 · Pflügers Archiv - European Journal of Physiology
Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs
Longyuan Gong, Danrui Cui, Xiufang Xiong, Yongchao Zhao · 2020 · Advances in experimental medicine and biology
Chimera induced protein degradation: PROTACs and beyond
Lina Yin, Qingzhong Hu · 2020 · European Journal of Medicinal Chemistry
PROTAC: A Novel Technology for Drug Development**
Jie Li, Jie‐Qing Liu · 2020 · ChemistrySelect
Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets
Wang, Yungang, Deng, Shouyan, Xu, Jie · 2020 · Cancer Biology and Medicine
Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues
Marta Pichlak, Tomasz Sobierajski, K. M. Błażewska, Edyta Gendaszewska‐Darmach · 2023 · Journal of Enzyme Inhibition and Medicinal Chemistry
Pharmacodynamic Models of Indirect Effects and Irreversible Inactivation with Turnover: Applicability to Mechanism-Based Modeling of Gene Silencing and Targeted Protein Degradation
Angelia F Wang, Vivaswath S. Ayyar · 2023 · Journal of Pharmaceutical Sciences
Ubiquitin recruiting chimera: more than just a PROTAC
Tatyana A. Grigoreva, Daria Novikova, Gerry Melino, Nick A. Barlev, Vyacheslav G. Tribulovich · 2024 · Biology Direct
A nuclear branched-chain amino acid catabolism pathway controls histone propionylation in pancreatic cancer
Christina Demetriadou, Michael Noji, Austin L. Good, Erick Mitchell-Velasquez, Sharan Venkatesh, Daniel S. Kantner, Jennifer L Pennise, Pedro Costa‐Pinheiro, Laura V. Pinheiro, Taku Harada et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Design of Class I/IV Bromodomain-Targeting Degraders for Chromatin Remodeling Complexes
Huda Zahid, Jeff P. Costello, Yao Li, Jennifer R. Kimbrough, Marisa Actis, Zoran Ranković, Qin Yan, William C. K. Pomerantz · 2023 · ACS Chemical Biology
Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues
Can Zhao, Henian Wang, Wenhu Zhan, Xiaoqing Lv, Xiaodong Ma · 2023 · Journal of Medicinal Chemistry
Alternative Approaches to Counter Multidrug-Resistant Bacterial Pathogens
Deepanshi Saxena, Rahul Maitra, Arunava Dasgupta, Sidharth Chopra · 2024 · Springer eBooks
MYCN and KAT2A form a feedforward loop to drive an oncogenic transcriptional program in neuroblastoma
Zhihui Liu, Jason J Hong, Xiyuan Zhang, Carly M. Sayers, Wendy Fang, Man Xu, Sydney M. Loria, Sakereh Maskal, Haiyan Lei, Haitao Wu et al. · 2025 · Oncogenesis
Reviewing the toolbox for degrader development in oncology
Joel O. Cresser-Brown, Graham P. Marsh, Hannah J. Maple · 2021 · Current Opinion in Pharmacology
Getting a Handle on Chemical Probes of Chomatin Readers
Jarod M. Waybright, Lindsey Ingerman James · 2020 · Future Medicinal Chemistry
From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins
Yvonne A. Nagel, Adrian Britschgi, Antonio Ricci · 2021 · Wiley eBooks
PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery?
Philipp M. Cromm, Craig M. Crews, Hilmar Weinmann · 2020 · Royal Society of Chemistry eBooks
Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC
Daria Torodii, Jacob Brian Holmes, Manuel Cordova, Pinelopi Moutzouri, Lotte van Beek, Fredrik Edfeldt, Erik Malmerberg, Stig D. Friis, Johan R. Johansson, Alexander G. Milbradt et al. · 2025 · Nature Communications
The Potential Impact of New Drug and Therapeutic Modalities on Drug Resistance to Renal Cell Carcinoma
Pedro Caetano-Pinto · 2023 · Anticancer Research
E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities
Bhaskar Basu, Satadeepa Kal, Subhajit Karmakar, Malini Basu, Mrinal K. Ghosh · 2023 · Life Sciences
Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity
Praveen Kumar Tiwari, Sai Reddy Doda, Raghu Vannam, Manish S. Hudlikar, Drew A. Harrison, Samuel Ojeda, Sumit Rai, Ann-Sophie Koglin, Angelique Gilbert, Christopher J. Ott · 2024 · Bioorganic & Medicinal Chemistry Letters
Design of bifunctional molecules to accelerate post-translational modifications: achievements and challenges
Yuxuan Wang, Yanyi He, Qidong You, Lei Wang · 2024 · Drug Discovery Today
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–4
Arduino Aleksander Mangoni, Catherine Guillou, Jean Jacques Vanden Eynde, Christopher Hulme, Josef Jampílek, Wěi Li, Katalin Prókai-Tátrai, Jarkko Rautio, Simona Collina, Tiziano Tuccinardi et al. · 2018 · Molecules
Medicinal chemistry approaches to the discovery and development of p300/CBP inhibitors for cancer therapy
Huan Wang, Dandan Song, Miao Miao, Simeng Wu, Jiao Wang, Zhe Huang, Hao Ding · 2025 · European Journal of Medicinal Chemistry
Targeting the Epigenetic Remodeler GCN5 Prevents Vascular Oxidative Stress and Endothelial Dysfunction in Obesity: Insights in Patients with Cardiometabolic Disease
Sarah Costantino, S A Mohammed, Alessandro Mengozzi, Emiliano Duranti, Valentina Delfine, Martin Andreas Geiger, Nazha Hamdani, Stefano Taddei, Stefano Masi, Agostino Virdis et al. · 2025 · High Blood Pressure & Cardiovascular Prevention
Developing Pharmacokinetic/Pharmacodynamic Relationships With PROTACs
John D. Harling, Paul Scott‐Stevens, Lu Gaohua · 2020 · Royal Society of Chemistry eBooks
Computational Modeling of PROTAC Ternary Complexes and Linker Design
Sven A. Miller, Grigorii V. Andrianov, Victoria Mischley, Khadija A. Wharton, Jesse J. Chen, John Karanicolas · 2022
Lysine Acetyltransferase 6 in Health and Disease
Yujing Tan, Jiani Wang, Fei Ma · 2025 · MedComm
Advantages of PROTACs in achieving selective degradation of homologous protein families
Luxi Yang, Xinfei Mao, Jingyi Zhang, Jing Shu, Wenhai Huang, Xiaowu Dong, Yinqiao Chen, Mingfei Wu · 2026 · Beilstein Journal of Organic Chemistry
Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives
Xing Yi Yan, Yuan Yuan Kang, Ze Yan Zhang, Ping Cheong Huang, Chang Yang, Hua Naranmandura · 2024 · Expert Opinion on Therapeutic Targets
Disruption of the SAGA CORE triggers collateral degradation of KAT2A
Paul Batty, H Beneder, Caroline Schätz, Gabriel Onea, Maciej Zaczek, Ana P. Kutschat, Miriam Abele, Sophie Müller, Giulio Superti‐Furga, Georg E. Winter et al. · 2026 · Nature Communications
Chromatin Regulatory Targets for Anticancer Therapeutics
Paige A. Barta, Trever R. Carter, Michael A. Erb · 2025 · Chemical Reviews
Multitargeted protein degradation: Integrating small-molecule, biomacromolecular, and nano-PROTACs for paradigm shifts in drug discovery
Jinghua Yang, Yujing Zhang, Miao Zhang, Dongming Xing, Chao Wang · 2025 · Materials Today Advances
Chemical Targeting of Histone Acetyltransferases
Qi Liu, Aimee L. Qi, Adam David Durbin, Jun Qi · 2024 · Royal Society of Chemistry eBooks
Transcriptomic and Metabolomic Analysis Reveals Multifaceted Impact of Gcn5 Knockdown in Drosophila Development
Youfeng Li, Yue Xu, Ruike Li, Sirui Huang, Qiong Wu, Jing Yan, Zhigang Jiang, Xiushan Wu, Fang Li, Yuequn Wang et al. · 2024 · Metabolites
The bromodomain acyl-lysine readers in human health and disease
Pata-Eting Kougnassoukou Tchara, Anahita Lashgari, Jean‐Philippe Lambert · 2023 · Elsevier eBooks
Targeted Protein Degradation by Proteolysis Targeting Chimeras
Wu Du · 2022
Application of PROTAC Technology in Drug Development
Prashant S. Kharkar, Atul L. Jadhav · 2022 · Methods and principles in medicinal chemistry
Broadening the horizon: The promise of PROTACs in non-malignant disorders
Liping Fu, Gongruixue Zeng, Yu Cao, Yueli He, Yaping Zhao, Chongmei Tian, Jinbai Chen, Hualin Feng, Jianjun Xi, Jingsong Shao et al. · 2026 · European Journal of Medicinal Chemistry
Insights into the structure and evolution of the human SAGA complex by affinity-ligand purification
Mylène Damilot, Thomas Schoeps, Làszlò Tora, Patrick Schultz, Luc Lebeau, Gábor Pápai, Adam Ben Shem · 2026 · Science Advances
Targeted Protein Degradation Chemical Probes
Carles Galdeano, Xavier Barril · 2020 · Royal Society of Chemistry eBooks
Experimental approaches toward histone acetyltransferase modulators as therapeutics
Deng Chen, Hannah Wapenaar, Frank J. Dekker · 2021 · Elsevier eBooks
Idegenerering i IT-bedrifter - åpenhet og nettverks betydning for idégenerering
Tony Andreas Liafjell · 2014 · NORA - Norwegian Open Research Archives
Prospective advances in medical epigenetics
Jiali Deng, Mengying Guo, Junjie Xiao · 2021 · Elsevier eBooks
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Eric Valeur · 2023 · Royal Society of Chemistry eBooks
Targeting the Acetylation Reader Family: Bromodomain Proteins
Martin P. Schwalm, Atoosa Karimi Babaahmadi, Suzanne Z. Ackloo, Stefan Knapp · 2024 · Royal Society of Chemistry eBooks
Drug Discovery for Chromatin Readers, Writers, Erasers, Remodelers and Epitranscriptomic Targets
2024 · Royal Society of Chemistry eBooks
Targeted Protein Degradation of Metalloenzymes
Conor O’Herin, Seth M. Cohen · 2025 · Wiley eBooks
CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-Driven Alveolar Rhabdomyosarcoma
Susu Zhang, Kathleen L. Engel, Assil Fahs, Ara Jo, Clare F. Malone, Kenneth N. Ross, Marissa A. Just, Brian Guedes, Diyana Granum, Kristianne Michelle Oristian et al. · 2026 · Cancer Discovery
Novel insights into the structure and evolution of the human SAGA complex by affinity-ligand purification
Mylène Damilot, Thomas Schoeps, Làszlò Tora, Patrick Schultz, Luc Lebeau, Gábor Pápai, Adam Ben Shem · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
Additional file 7 of Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-κB and H3K9Ac blockade
Jinteng Li, Ye, Feng, Xu, Xiaojun, Peitao Xu, Wang, Peng, Zheng, Guan, Guiwen Ye, Yu, Wenhui, Zepeng Su, Lin, Jiajie et al. · 2023 · Figshare
Additional file 6 of Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-κB and H3K9Ac blockade
Jinteng Li, Ye, Feng, Xu, Xiaojun, Peitao Xu, Wang, Peng, Zheng, Guan, Guiwen Ye, Yu, Wenhui, Zepeng Su, Lin, Jiajie et al. · 2023 · Figshare
Additional file 2 of Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-κB and H3K9Ac blockade
Jinteng Li, Ye, Feng, Xu, Xiaojun, Peitao Xu, Wang, Peng, Zheng, Guan, Guiwen Ye, Yu, Wenhui, Zepeng Su, Lin, Jiajie et al. · 2023 · Figshare
Additional file 8 of Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-κB and H3K9Ac blockade
Jinteng Li, Ye, Feng, Xu, Xiaojun, Peitao Xu, Wang, Peng, Zheng, Guan, Guiwen Ye, Yu, Wenhui, Zepeng Su, Lin, Jiajie et al. · 2023 · Figshare
Additional file 1 of Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-κB and H3K9Ac blockade
Jinteng Li, Ye, Feng, Xu, Xiaojun, Peitao Xu, Wang, Peng, Zheng, Guan, Guiwen Ye, Wenhui Yu, Zepeng Su, Lin, Jiajie et al. · 2023 · Figshare
Additional file 4 of Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-κB and H3K9Ac blockade
Jinteng Li, Ye, Feng, Xu, Xiaojun, Peitao Xu, Wang, Peng, Zheng, Guan, Guiwen Ye, Yu, Wenhui, Zepeng Su, Lin, Jiajie et al. · 2023 · Figshare
Additional file 3 of Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-κB and H3K9Ac blockade
Jinteng Li, Ye, Feng, Xu, Xiaojun, Peitao Xu, Wang, Peng, Zheng, Guan, Guiwen Ye, Yu, Wenhui, Zepeng Su, Lin, Jiajie et al. · 2023 · Figshare
Additional file 5 of Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-κB and H3K9Ac blockade
Jinteng Li, Ye, Feng, Xu, Xiaojun, Peitao Xu, Wang, Peng, Zheng, Guan, Guiwen Ye, Yu, Wenhui, Zepeng Su, Lin, Jiajie et al. · 2023 · Figshare
Additional file 9 of Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-κB and H3K9Ac blockade
Jinteng Li, Ye, Feng, Xu, Xiaojun, Peitao Xu, Wang, Peng, Zheng, Guan, Guiwen Ye, Yu, Wenhui, Zepeng Su, Lin, Jiajie et al. · 2023 · Figshare
Discovery and Optimization of Orally Bioavailable Heterobifunctional Degraders of KAT2A/B for the Treatment of Cancer
James Neef, Kimberly S. Straley, Chinmoy Mukherjee, Amol Tipnis, Suleman R. Maujan, Maulasri Bhatta, Sambad Sharma, Sara L. Sinicropi-Yao, Joe DeBartolo, Andrew J. McRiner et al. · 2026 · Journal of Medicinal Chemistry
KAT2B inhibits cholangiocarcinoma proliferation by binding with histone demethylase KDM6B
Rongfang Qiu, Ziwei Xu, Hui Meng, Yishan Wang, Qinqqing Wu, Lulu Zeng, Haixia Zhao, Zian Mao, Qiaoyou Weng, Jianfei Tu et al. · 2026 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Isoform-specific cofactor recruitment through the intrinsically disordered N-terminus of p63 underlies differential transcriptional activities
Marina F. Nogueira, Michael J. Moore, Aparna Riti Biswas, Michael P. Meers, Sidharth V. Puram · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
Development of a Lysine‐Reactive Targeted Covalent Inhibitor for the P300/CBP‐Associated Factor Bromodomain Through Structure‐Based Design
Richard Ede, Kerstin E. Peterson, Richard Kofi Begyinah, Irin Pottanani Tom, Jason Ochoada, Molly Sneddon, Ana Katrina Y. Tiu, Marcus Fischer, Anang A. Shelat, William C. K. Pomerantz · 2026 · ChemMedChem
Eyes Toward the Clinic: Selective Inhibition and Degradation Approaches to Bromodomain‐Containing Proteins
Cole R. Scholtz, William C. K. Pomerantz · 2026 · ChemBioChem
Linker attachment points: “finishing touch” in PROTAC design
qiaojuan jiang, Hua-Sheng Shi, Chuan-Sheng Zhao, Zi-Yi Wang, Mei-Meng Yu, Xin-Yue Zhang, Cong-Jun Liu · 2026 · RSC Medicinal Chemistry
Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML Subtypes
Anagha Deshpande, Cho-Ying Chiang, Marlenne Perales, Neha Niranjan, Neelam Sinha, Darren Finlay, Alexandra Stevens, Emily Zahn, Benjamin A. Garcia, Irmela Jeremias et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
Step-brothers in arms, SAGA and ATAC co-activator complexes, use different strategies
Francesca Rizzo, Adam Ben Shem, H. T. Marc Timmers, Till Bartke, Stéphane D. Vincent, Làszlò Tora · 2026 · The EMBO Journal
Pharmacological targeting of GCN5/PCAF (KAT2A/B): current drug discovery strategies and translational potential
Priyanka Pandey, Prajjval Mishra, Pritam Biswas, Sourav Chatterjee, Tapas Kumar Kundu · 2026 · Drug Discovery Today
David Tough: immunological memories
Persephone Borrow · 2026 · Clinical & Experimental Immunology
Identification, Structure–Activity Relationship (SAR), and Biological Evaluation of New Chemical Series as Malaria Parasite Pf GCN5 Bromodomain Inhibitors
Pedro Martín-Acosta, Abbas H. K. Al Temimi, Luma G. Magalhães, Juan Salamanca Viloria, José Ignacio Martı́n Hernando, Ana I. Villegas, Virginia Franco Hidalgo, Joel McMillan, Andrew Plater, Mark Anderson et al. · 2026 · ACS Omega
KMT2E recruitment by H3 serotonylation regulates neurodevelopmental chromatin dynamics
Jennifer C. O’Chan, Benjamin H. Weekley, Celi Yang, Min Chen, Ashley M. Cunningham, Sohini Dutta, Winnie Chen, Rasika R. Iyer, Newaz I. Ahmed, Bulent Cetin et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency
Ran Tao, Serap Erkek, Beisi Xu, Yurika Matsui, Priya Mittal, Kyle S. Smith, Yiran Li, David Filipovic, Ruijie Xu, Qingsong Gao et al. · 2026 · Nature Genetics
In vivo fate-guided design of efficient delivery systems for PROTACs: From molecular rationales to clinical progress
Wei Zhang, Shiyuan Li, Yao Yao, Yuling Mao, WenJun Jiang, Shuai Li · 2026 · Pharmacological Research
The bromodomain and its contribution to human health
Naomie Linteau, Jean-Philippe Lambert · 2026 · Elsevier eBooks
BindingDB Entry 50021924: Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review.
BindingDB · 2025 · UC San Diego
BindingDB Entry 50018749: PROTAC: A promising technology for cancer treatment.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50019525: PROTACS: A technology with a gold rush-like atmosphere.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50007767: Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
BindingDB · 2021 · UC San Diego
BindingDB Entry 50019232: Development of Human Carbonic Anhydrase II Heterobifunctional Degraders.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50019825: Developments of PROTACs technology in immune-related diseases.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50006137: Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50015475: Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders.
BindingDB · 2023 · UC San Diego
BindingDB Entry 50019142: Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50010598: Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.
BindingDB · 2021 · UC San Diego
BindingDB Entry 50012315: Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
BindingDB · 2022 · UC San Diego
BindingDB Entry 50020612: Recent Advances on Small-Molecule Bromodomain-Containing Histone Acetyltransferase Inhibitors.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50006856: Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
BindingDB · 2021 · UC San Diego
BindingDB Entry 50023478: PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications.
BindingDB · 2026 · UC San Diego
BindingDB Entry 50018350: Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
BindingDB · 2024 · UC San Diego
BindingDB Entry 50007822: Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.
BindingDB · 2021 · UC San Diego
BindingDB Entry 50020203: Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues.
BindingDB · 2024 · UC San Diego
BindingDB Entry 50021668: Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
BindingDB · 2025 · UC San Diego